Actelion falls on Veletri failure

Actelion (SWX:ATLN) was down CHF37.50 (25%) to CHF115.50 on Monday after announcing that it halted its Phase III VERITAS 1 and 2 trials of Veletri tezosentan to treat

Read the full 288 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE